Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: An initial experience

Tsyh Jyi Hsieh, Chun Wei Li, Hung Yi Chuang, Gin Chung Liu, Chien-Kuo Wang

研究成果: Article

19 引文 (Scopus)

摘要

PURPOSE:: To investigate the value of in vivo proton (H) magnetic resonance spectroscopy (MRS) in longitudinally monitoring the treatment response of malignant musculoskeletal tumors under chemotherapy. MATERIALS AND METHODS:: Twenty-three studies in 3 patients with bone and soft-tissue tumors (2 lymphomas and 1 alveolar soft part sarcoma) were included in the study. The dynamic contrast-enhanced magnetic resonance (MR) imaging and single-voxel proton MRS with 135 milliseconds of echo time were carried out using a whole-body 1.5-T scanner and a surface coil. The volume of interest within the lesion was positioned on the area of early enhancement according to the finding of the first dynamic contrast-enhanced MR imaging with subtraction. The choline and water intensities were measured at the peak areas at 3.2 and 4.5 ppm. The choline-water ratios were calculated as well. Statistical analysis was performed by using Kruskal-Wallis 1-way analysis of variance test ().(Table is included in full-text article.) RESULTS: The changes observed on the dynamic contrast-enhanced MR images and tumor size after chemotherapy fell into 2 clearly distinct patterns: subsequent partial response (patients 1 and 2) and progressive disease (patient 3). The choline concentration, choline-volume ratio, and choline-water ratio in the first 2 patients were reduced substantially to zero in the follow-up MRS. In the remaining patient, the choline, choline-volume ratio, and choline-water ratio remained high in the follow-up MRS. The water concentration and water-volume ratio between the 3 patients showed significant statistical differences (Kruskal-Wallis test, P ≤ 0.004 and 0.039). CONCLUSION: In vivo proton MRS is technically feasible for the evaluation of musculoskeletal tumors. Choline can be detected in malignant bone and soft-tissue tumors, and the early metabolite changes after chemotherapy can also be identified in the in vivo proton MRS by using a standard clinical-use 1.5-T MR scanner and a surface coil. The decline of choline after treatment in malignant bone and soft-tissue tumors correlates with the response of the dynamic contrast MR images and the tumor size. The information provided with MR imaging and proton MRS may improve the diagnostic specificity of MR examination in the follow-up of tumor treatment.

原文English
頁(從 - 到)987-994
頁數8
期刊Journal of computer assisted tomography
32
發行號6
DOIs
出版狀態Published - 2008 十一月 1

指紋

Choline
Drug Therapy
Magnetic Resonance Spectroscopy
Neoplasms
Water
Magnetic Resonance Imaging
Bone and Bones
Alveolar Soft Part Sarcoma
Proton Magnetic Resonance Spectroscopy
Lymphoma
Analysis of Variance
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

引用此文

@article{6f93ccd661224a28aa2c41a4c4240dd5,
title = "Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: An initial experience",
abstract = "PURPOSE:: To investigate the value of in vivo proton (H) magnetic resonance spectroscopy (MRS) in longitudinally monitoring the treatment response of malignant musculoskeletal tumors under chemotherapy. MATERIALS AND METHODS:: Twenty-three studies in 3 patients with bone and soft-tissue tumors (2 lymphomas and 1 alveolar soft part sarcoma) were included in the study. The dynamic contrast-enhanced magnetic resonance (MR) imaging and single-voxel proton MRS with 135 milliseconds of echo time were carried out using a whole-body 1.5-T scanner and a surface coil. The volume of interest within the lesion was positioned on the area of early enhancement according to the finding of the first dynamic contrast-enhanced MR imaging with subtraction. The choline and water intensities were measured at the peak areas at 3.2 and 4.5 ppm. The choline-water ratios were calculated as well. Statistical analysis was performed by using Kruskal-Wallis 1-way analysis of variance test ().(Table is included in full-text article.) RESULTS: The changes observed on the dynamic contrast-enhanced MR images and tumor size after chemotherapy fell into 2 clearly distinct patterns: subsequent partial response (patients 1 and 2) and progressive disease (patient 3). The choline concentration, choline-volume ratio, and choline-water ratio in the first 2 patients were reduced substantially to zero in the follow-up MRS. In the remaining patient, the choline, choline-volume ratio, and choline-water ratio remained high in the follow-up MRS. The water concentration and water-volume ratio between the 3 patients showed significant statistical differences (Kruskal-Wallis test, P ≤ 0.004 and 0.039). CONCLUSION: In vivo proton MRS is technically feasible for the evaluation of musculoskeletal tumors. Choline can be detected in malignant bone and soft-tissue tumors, and the early metabolite changes after chemotherapy can also be identified in the in vivo proton MRS by using a standard clinical-use 1.5-T MR scanner and a surface coil. The decline of choline after treatment in malignant bone and soft-tissue tumors correlates with the response of the dynamic contrast MR images and the tumor size. The information provided with MR imaging and proton MRS may improve the diagnostic specificity of MR examination in the follow-up of tumor treatment.",
author = "Hsieh, {Tsyh Jyi} and Li, {Chun Wei} and Chuang, {Hung Yi} and Liu, {Gin Chung} and Chien-Kuo Wang",
year = "2008",
month = "11",
day = "1",
doi = "10.1097/RCT.0b013e31815b9ce9",
language = "English",
volume = "32",
pages = "987--994",
journal = "Journal of Computer Assisted Tomography",
issn = "0363-8715",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy

T2 - An initial experience

AU - Hsieh, Tsyh Jyi

AU - Li, Chun Wei

AU - Chuang, Hung Yi

AU - Liu, Gin Chung

AU - Wang, Chien-Kuo

PY - 2008/11/1

Y1 - 2008/11/1

N2 - PURPOSE:: To investigate the value of in vivo proton (H) magnetic resonance spectroscopy (MRS) in longitudinally monitoring the treatment response of malignant musculoskeletal tumors under chemotherapy. MATERIALS AND METHODS:: Twenty-three studies in 3 patients with bone and soft-tissue tumors (2 lymphomas and 1 alveolar soft part sarcoma) were included in the study. The dynamic contrast-enhanced magnetic resonance (MR) imaging and single-voxel proton MRS with 135 milliseconds of echo time were carried out using a whole-body 1.5-T scanner and a surface coil. The volume of interest within the lesion was positioned on the area of early enhancement according to the finding of the first dynamic contrast-enhanced MR imaging with subtraction. The choline and water intensities were measured at the peak areas at 3.2 and 4.5 ppm. The choline-water ratios were calculated as well. Statistical analysis was performed by using Kruskal-Wallis 1-way analysis of variance test ().(Table is included in full-text article.) RESULTS: The changes observed on the dynamic contrast-enhanced MR images and tumor size after chemotherapy fell into 2 clearly distinct patterns: subsequent partial response (patients 1 and 2) and progressive disease (patient 3). The choline concentration, choline-volume ratio, and choline-water ratio in the first 2 patients were reduced substantially to zero in the follow-up MRS. In the remaining patient, the choline, choline-volume ratio, and choline-water ratio remained high in the follow-up MRS. The water concentration and water-volume ratio between the 3 patients showed significant statistical differences (Kruskal-Wallis test, P ≤ 0.004 and 0.039). CONCLUSION: In vivo proton MRS is technically feasible for the evaluation of musculoskeletal tumors. Choline can be detected in malignant bone and soft-tissue tumors, and the early metabolite changes after chemotherapy can also be identified in the in vivo proton MRS by using a standard clinical-use 1.5-T MR scanner and a surface coil. The decline of choline after treatment in malignant bone and soft-tissue tumors correlates with the response of the dynamic contrast MR images and the tumor size. The information provided with MR imaging and proton MRS may improve the diagnostic specificity of MR examination in the follow-up of tumor treatment.

AB - PURPOSE:: To investigate the value of in vivo proton (H) magnetic resonance spectroscopy (MRS) in longitudinally monitoring the treatment response of malignant musculoskeletal tumors under chemotherapy. MATERIALS AND METHODS:: Twenty-three studies in 3 patients with bone and soft-tissue tumors (2 lymphomas and 1 alveolar soft part sarcoma) were included in the study. The dynamic contrast-enhanced magnetic resonance (MR) imaging and single-voxel proton MRS with 135 milliseconds of echo time were carried out using a whole-body 1.5-T scanner and a surface coil. The volume of interest within the lesion was positioned on the area of early enhancement according to the finding of the first dynamic contrast-enhanced MR imaging with subtraction. The choline and water intensities were measured at the peak areas at 3.2 and 4.5 ppm. The choline-water ratios were calculated as well. Statistical analysis was performed by using Kruskal-Wallis 1-way analysis of variance test ().(Table is included in full-text article.) RESULTS: The changes observed on the dynamic contrast-enhanced MR images and tumor size after chemotherapy fell into 2 clearly distinct patterns: subsequent partial response (patients 1 and 2) and progressive disease (patient 3). The choline concentration, choline-volume ratio, and choline-water ratio in the first 2 patients were reduced substantially to zero in the follow-up MRS. In the remaining patient, the choline, choline-volume ratio, and choline-water ratio remained high in the follow-up MRS. The water concentration and water-volume ratio between the 3 patients showed significant statistical differences (Kruskal-Wallis test, P ≤ 0.004 and 0.039). CONCLUSION: In vivo proton MRS is technically feasible for the evaluation of musculoskeletal tumors. Choline can be detected in malignant bone and soft-tissue tumors, and the early metabolite changes after chemotherapy can also be identified in the in vivo proton MRS by using a standard clinical-use 1.5-T MR scanner and a surface coil. The decline of choline after treatment in malignant bone and soft-tissue tumors correlates with the response of the dynamic contrast MR images and the tumor size. The information provided with MR imaging and proton MRS may improve the diagnostic specificity of MR examination in the follow-up of tumor treatment.

UR - http://www.scopus.com/inward/record.url?scp=62149111108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149111108&partnerID=8YFLogxK

U2 - 10.1097/RCT.0b013e31815b9ce9

DO - 10.1097/RCT.0b013e31815b9ce9

M3 - Article

C2 - 19204465

AN - SCOPUS:62149111108

VL - 32

SP - 987

EP - 994

JO - Journal of Computer Assisted Tomography

JF - Journal of Computer Assisted Tomography

SN - 0363-8715

IS - 6

ER -